KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Net Margin (2016 - 2026)

Gilead Sciences filings provide 17 years of Net Margin readings, the most recent being 31.9% for Q4 2025.

  • On a quarterly basis, Net Margin rose 836.0% to 31.9% in Q4 2025 year-over-year; TTM through Dec 2025 was 30.08%, a 2841.0% increase, with the full-year FY2025 number at 28.9%, up 2724.0% from a year prior.
  • Net Margin hit 31.9% in Q4 2025 for Gilead Sciences, down from 39.28% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 39.28% in Q3 2025 to a low of 62.38% in Q1 2024.
  • Median Net Margin over the past 5 years was 22.66% (2022), compared with a mean of 17.91%.
  • Biggest five-year swings in Net Margin: surged 9158bps in 2021 and later plummeted -7788bps in 2024.
  • Gilead Sciences' Net Margin stood at 5.19% in 2021, then soared by 326bps to 22.1% in 2022, then decreased by -10bps to 19.9% in 2023, then grew by 18bps to 23.54% in 2024, then skyrocketed by 35bps to 31.9% in 2025.
  • The last three reported values for Net Margin were 31.9% (Q4 2025), 39.28% (Q3 2025), and 27.69% (Q2 2025) per Business Quant data.